The European Pharmacopoeia and certificates of suitability (CEP)

Andrew McMath Ph.D.
European Directorate for the Quality of Medicines (EDQM)

Presented by: Andrew McMath
Scientific Officer, EDQM
European Directorate for the Quality of Medicines & HealthCare (EDQM)

A Council of Europe Directorate, based on the Convention on the Elaboration of a European Pharmacopoeia (PA, 1964)

Mission: to contribute to a basic human right: access to good quality medicines and healthcare
European Pharmacopoeia (Ph. Eur.)

• Protecting public health - one common compulsory standard.

• The Ph. Eur. is the official pharmacopoeia in Europe – complemented by national pharmacopoeias for texts of interest to only one Member State.

• Mandatory at the same date in 37 Member States (CoE) and the EU.

• Legally binding quality standards for ALL medicinal products in its member states, i.e. raw material, preparations, dosage forms, containers must comply with the Ph. Eur. requirements when they exist.
European Pharmacopoeia Monographs Today

- Active substances (organic, inorganic)
- Excipients
- Substances of biological origin and biotechnology (insulin, somatropin...)
- Herbal drugs, essential oils and fats, preparations
- Radiopharmaceuticals
- Vaccines, sera (human, veterinary), blood derivatives
- Homeopathic preparations
- General monographs on dosage forms
- General texts on quality issues and standard analytical methods

⇒ More than 2200 monographs
General Notices

Put at the very beginning of the Ph. Eur., they address general issues and are aimed at providing basic information to the user.

► Apply to all texts
► Rules to understand texts, conventional expressions

Essential reading before starting to use Monographs
Flexibility in the Ph.Eur. -Alternative methods

- Ph. Eur. tests are reference methods, essential in cases of dispute.
- Compliance is required, but alternative methods may be used as long as they lead to the same pass/fail result. It is the responsibility of the user to demonstrate their suitability. Approval of the competent authority is necessary in many cases.
Flexibility in the Ph.Eur. – General Notices

“An article is not of Pharmacopoeia quality unless it complies with all the requirements stated in the monograph. This does not imply that performance of all the tests in a monograph is necessarily a prerequisite for a manufacturer in assessing compliance with the Pharmacopoeia before release of a product.....
An enhanced approach to quality control could utilise process analytical technology (PAT) and/or real-time release testing (including parametric release) strategies as alternatives to end-product testing alone.”

(Suppl. 8.2.)
What does compliance mean?

- Compliance with a **monograph**
- All **mandatory** parts of a monograph.
- Compliance **until time of use** for raw materials, ingredients.
- Compliance **throughout period of validity** for preparations.
- In-use compliance decided by licensing authority for each preparation.
What must comply?

- Mandatory for all substances for pharmaceutical use
- Ingredients (incl. excipients) of final formulation
- Components of solvents, buffers etc. in or used to make up final formulation
- Reagents? Not usually needed for upstream use
Validation of Pharmacopoeial methods

The test methods .... have been validated ..... Unless otherwise stated in the monograph or general chapter, validation of the test methods by the analyst is not required.”

“When implementing a pharmacopoeial method, the user must assess if and to what extent the suitability of the method under the actual conditions of use needs to be demonstrated «

8th edition
Why general chapters?

Analytical methods:

- Editorial convenience: avoid repeating standard methods in each monograph
- Provide standard methods that can be used where there is no monograph
- Give general requirements for equipment, equipment verification
- Not mandatory “per se” but when referred to in a monograph, they become part of the standard

Also other types of general chapters...
Examples

Chapter 5.10 Control of impurities in substances for pharmaceutical use ➔ cross referenced in General monograph 2034 Substances for pharmaceutical use ➔ chapter 5.10 is to be applied to all API (whether or not an individual monograph exists in the Ph. Eur.)

Chapter 5.2.8 Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products ➔ creation of General monograph 1483 Products with risk of transmitting agents of animal spongiform encephalopathies which cross-references the chapter 5.2.8 ➔ chapter 5.2.8 is legally binding
International Harmonisation

• Pharmacopoeial Discussion Group (PDG): an informal structure (members: JP, Ph. Eur., USP + WHO as observer)

• Aim of harmonisation of general chapters: to arrive at interchangeable methods or requirements.


• PDG state of work: http://pharmeuropa.edqm.eu/home/menupage/English/Pharmacopoeial%20Harmonisation/PDG_State_of_Work_E.pdf
Why general monographs?

Two types:

- General monographs on classes of substances
- General monographs on dosage forms

- Apply to all products ("General monographs apply to all substances and preparations within the scope of the Definition section of the general monograph, except where a preamble limits the application, for example to substances and preparations that are the subject of a monograph of the pharmacopoeia." General notices)

- No cross-reference in individual monographs

CHECK WHICH GENERAL MONOGRAPH APPLIES!
General monographs (cont.)

- "Classes" defined by different criteria: production method, origin, risk factors
- Aspects that cannot be treated in each individual monograph
  - Residual solvents
  - TSE/BSE
  - Pesticides in herbals
  - etc. ...
Which has priority, a general monograph or an individual monograph?

- Basic principle is that general and individual monographs are complementary and one does not overrule the other.

- Exceptions are clearly indicated either in the general monograph or in the individual one.
Substances for pharmaceutical use (2034)

• Requirements laid down in this general monograph apply to all substances for pharmaceutical use whether or not the substance is covered by an individual monograph.

• “Where a substance for pharmaceutical use not described in an individual monograph of the Pharmacopoeia is used in a medicinal product prepared for the special needs of individual patients, the need for compliance with the present general monograph is decided in the light of a risk assessment that takes account of the available quality of the substance and its intended use”.
Pharmaceutical Preparations (2619)

- reference source of standards in the European Pharmacopoeia on active substances, excipients and dosage forms, which are to be applied in the manufacture/preparation of pharmaceuticals, but not a guide on how to manufacture as there is specific guidance available covering methods of manufacture and associated controls.

- does not cover investigational medicinal products, but competent authorities may refer to pharmacopoeial standards when authorising clinical trials using investigational medicinal products.
General monographs on dosage forms

- Contain requirements common to all dosage forms of the type defined (tablets, capsules, parenteral preparations, etc.)
- Classified by pharmaceutical form/route of administration
- Applied during licensing
- Framework specification: acceptance criteria and extra tests are proposed by manufacturer and approved by competent authority
The Certification Procedure

- To demonstrate that the quality of a substance is controlled by the Ph. Eur. monograph and additional tests if needed ("Chemical CEP" or "Herbal CEP")

- To guarantee compliance with the general monograph on Products with TSE risk ("TSE CEP")
The Certification Procedure (cont.)

• CEPs are accepted in 37 Member States + EU, and beyond (e.g. Canada, Australia, Singapore, South Africa, etc.)

• Directive 2003/63/EC: Where the active substance and/or raw and starting material or excipient(s) are the subject of a monograph of the EP, the applicant can apply for a certificate of suitability that, where granted by the EDQM, shall be presented in the relevant section of the Module. Those certificates of suitability ...are deemed to replace the relevant data of the corresponding sections described in the Module...
The CEP procedure (cont.)

Provides:

- Centralised assessment - saves time and resources
- Information on the need to update Ph. Eur. monographs
- Facilitates management of MAAs and variations
- Application submitted directly to EDQM by the manufacturer of the pharmaceutical substance
- Confidentiality of data

- Governing document for the Certification procedure:
  - Resolution AP-CSP (07) 1
Scope of the CEP Procedure

• Substances described in monographs in the Ph. Eur. (Active substances, excipients, herbal drugs / herbal preparations)
  •→ “Chemical” or “Herbal” CEP

• Products with risk of TSE (SM, intermediates, reagents,..)
  •→ “TSE” CEP

• Open to any manufacturer regardless of geographical origin
Out of Scope of the CEP Procedure

- Substances not included in Ph. Eur.
- Biologicals (PA/PH/CEP (09) 152 rev 01)
- Human tissues derivatives, blood derivatives, vaccines
- Mixtures of API with excipients (unless justified)
- Substances which do not comply with the Definition section of the monograph
- Finished products
How to apply for a CEP

- Application form (for new application) available on the website. It contains tables to be filled in, statements and declarations to be signed
- Quality Overall Summary (see template on the EDQM website)
- Fees:

<table>
<thead>
<tr>
<th>Reference</th>
<th>Item</th>
<th>Fee</th>
<th>Tick as appropriate</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEP03</td>
<td>Simple certificate (chemical or TSE or herbal product)</td>
<td>3000 €</td>
<td></td>
</tr>
<tr>
<td>CEP13</td>
<td>Certificate for chemical purity and sterility</td>
<td>6000 €</td>
<td></td>
</tr>
<tr>
<td>CEP01</td>
<td>Double certificate (chemical + TSE)</td>
<td>6000 €</td>
<td></td>
</tr>
<tr>
<td>CEP14</td>
<td>Double certificate (chemical + TSE) covering also sterility</td>
<td>9000 €</td>
<td></td>
</tr>
</tbody>
</table>

- Electronic submissions encouraged (eCTD, NeeS, pdf)
- Dossier in English (preferably) or French (see documents on the EDQM website)
How it works

To be updated:
- at any change (notification, minor/major)
- after 5 years (renewal)

Application

Request for inspection

Revision of monograph

Validation at receipt

Evaluation (2 assessors) + TAB if necessary

CEP granted

Refusal

Request for add info

Possibility of hearing

Informing licensing authorities

Transfer to the Ph. Eur. experts group

The European Pharmacopoeia and certificates of suitability (CEP)
What does it mean?

• A chemical CEP **certifies** that the quality of the substance is suitably controlled by the Ph. Eur. monograph with addition of tests if necessary (mentioned on the CEP)

• A TSE CEP **certifies** that the substance complies with the EMA NfG on minimising the TSE risk. It **DOES NOT** certify that the quality of the substance is suitably controlled by a specific Ph. Eur. monograph

• It **DOES NOT** replace a certificate of analysis

• It **IS NOT** a GMP certificate
Certification - Inspection

- Integral part of the Certification Procedure
- Performed before or after the CEP is granted
- Aim: to verify the compliance with
  - Submitted dossier
  - EU GMP Part II
  - EU GMP Annexes (e.g. Annex 1 / sterile substances)

Actions are taken immediately after the inspection in case of major or critical deficiencies (public health issue)
Repartition of manufacturers (2012)

1. India 222 sites
2. China 211 sites
3. Italy 84 sites
4. France 65 sites
5. Germany 60 sites
Key figures

- Since 1994, more than 5500 CEP applications received for 850 different substances
- Currently more than 3600 valid CEPs
- >1000 manufacturers from 50 different countries
- These numbers change frequently as new applications are received and existing CEPs are revised daily.
Thank you for your attention